BTX - BioTime, Inc.
1.2800 +0.03 (2.40%)
After hours: 5:21PM EDT
| Previous Close | 1.2000 |
| Open | 1.2000 |
| Bid | 1.2400 x 2200 |
| Ask | 1.2500 x 1400 |
| Day's Range | 1.1800 - 1.2600 |
| 52 Week Range | 0.6600 - 2.8100 |
| Volume | 539,676 |
| Avg. Volume | 1,092,153 |
| Market Cap | 186.701M |
| Beta (3Y Monthly) | 3.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3620 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Business Wire•2 days ago
BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. , a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration with geographic atrophy, will be presented at the 2019 Association ...
- Zacks•6 days ago
BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know
BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks•16 days ago
Top Ranked Momentum Stocks to Buy for April 2nd
Top Ranked Momentum Stocks to Buy for April 2nd
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 BioTime Inc Earnings Call
- Business Wire•last month
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co.
- Associated Press•last month
BioTime: 4Q Earnings Snapshot
The Alameda, California-based company said it had a loss of 35 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The results met Wall Street expectations. The average ...
- Business Wire•last month
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
ALAMEDA, Calif.-- -- Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, ...
- Business Wire•last month
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc. (Asterias), whereby BioTime has acquired through a merger, all of the remaining outstanding common stock of Asterias which was not previously owned by BioTime. As a result of the acquisition, Asterias became a wholly-owned subsidiary of BioTime and the operations of BioTime and Asterias have combined. Notably, 98% of BioTime votes cast and 96% of Asterias votes cast were in favor of the merger.
- Business Wire•last month
BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, March 14th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2018 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.
- Business Wire•last month
BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc., will present the 14th Annual Scientific Meeting of the Association For Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 at 1pm EDT, as part of Session 12: “Disruptive Technologies: Ophthalmic Tools and Methods That Have Changed The Ways We See The Eye”. AOPT 2019 will be held March 7-10.
- GlobeNewswire•2 months ago
BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif., Feb. 26, 2019 -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated.
- GlobeNewswire•2 months ago
Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress toward its commitment to become a leading cell therapy company by focusing on clinical-stage cell therapy product candidates with promising human data and supporting their development in part through targeted transactions among its affiliated companies,” stated Brian M. Culley, Chief Executive Officer of BioTime, Inc.
- ACCESSWIRE•2 months ago
Most Intriguing Companies on the New LD Micro Index
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Friday, LD Micro reinstituted their nearly 1000 company index of micro-caps, with the belief that our industry needs a truly accurate indicator of what is ...
- GlobeNewswire•3 months ago
BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis. As outlined in OncoCyte’s announcement, the R&D validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVu™ on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
- Business Wire•3 months ago
AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
ALAMEDA, Calif.-- -- 30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity ...
- GlobeNewswire•3 months ago
BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
Traditionally, the sub-retinal space is accessed via vitrectomy (removal of the vitreous, the gel-like substance that fills the eye), followed by an injection into the eye and through the retina. Orbit Biomedical’s injection system is designed to precisely and consistently deliver therapeutics to the sub-retinal space via a suprachoroidal route, avoiding the need for a vitrectomy and perforation of the retina. “Orbit Biomedical’s specifically-designed device offers surgeons an innovative solution for the delivery of therapies to the sub-retinal space, a well-known challenge in ophthalmology,” stated Brian M. Culley, Chief Executive Officer of BioTime.
- GlobeNewswire•3 months ago
BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. "I’m excited to welcome Brandi to the BioTime team during this critical period in which we increase the focus on our clinical-stage product candidates and improve our business structure through recently-announced and pending transactions involving our affiliated companies, AgeX (NYSE American: AGE) and Asterias (NYSE American: AST),” stated Brian M. Culley, Chief Executive Officer of BioTime.
- Business Wire•3 months ago
BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA. “Our vision is to build BioTime into the premiere cell therapy company, pioneering whole-cell transplants to address unmet medical conditions such as macular degeneration and spinal cord injury1, which have not yielded to small molecule approaches,” stated Brian M. Culley, Chief Executive Officer of BioTime. “Awareness of our mission is vital and our presentation at Biotech Showcase is one of our first opportunities to share our updated plans with a broad audience and build support for BioTime’s short- and long-term objectives.
- Business Wire•3 months ago
AgeX Therapeutics to Present at Biotech Showcase 2019
AgeX Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.
- Insider Monkey•4 months ago
BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was BioTime, Inc. (NYSEAMEX:BTX). BioTime, Inc. (NYSEAMEX:BTX) investors should be aware […]
- Business Wire•4 months ago
BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem®, BioTime’s proprietary hydrogel delivery platform technology, may mitigate ischemic brain injury and restore functional benefits by reducing neuroinflammation. The article entitled, “Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke,” was published in the International Journal of Molecular Sciences and is authored by clinicians at the Stanford University School of Medicine, Department of Neurosurgery.
- GlobeNewswire•4 months ago
New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•5 months ago
BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 at 8am Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
